Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication

Novel TLR2-binding adjuvant induces enhanced T cell responses and tumor eradication

Abstract Background Ligands for the Toll-like receptor (TLR) family can induce activation of cells of the innate immune system and are widely studied for their potential to enhance adaptive immunity. Conjugation of TLR2-ligand Pam3CSK4 to synthetic long peptides (SLPs) was shown to strongly enhance...

Full description

Bibliographic Details
Main Authors: Gijs G. Zom, Marian M. J. H. P. Willems, Selina Khan, Tetje C. van der Sluis, Jan Willem Kleinovink, Marcel G. M. Camps, Gijsbert A. van der Marel, Dmitri V. Filippov, Cornelis J. M. Melief, Ferry Ossendorp
Format: Article
Language:English
Published: BMJ Publishing Group 2018-12-01
Series:Journal for ImmunoTherapy of Cancer
Subjects:
Toll-like receptor 2
Adjuvant
Cancer vaccine
Peptide vaccination
T cell activation
Online Access:http://link.springer.com/article/10.1186/s40425-018-0455-2

Internet

http://link.springer.com/article/10.1186/s40425-018-0455-2

Similar Items